BioLineRx (NASDAQ:BLRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report report published on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reduced their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, November 25th.

BioLineRx Trading Up 0.2 %

NASDAQ BLRX opened at $0.14 on Friday. BioLineRx has a 12 month low of $0.14 and a 12 month high of $1.52. The company’s 50-day moving average price is $0.29 and its 200-day moving average price is $0.51. The stock has a market cap of $11.42 million, a PE ratio of -0.65 and a beta of 1.46. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11.

Institutional Trading of BioLineRx

Several institutional investors and hedge funds have recently made changes to their positions in the company. CVI Holdings LLC purchased a new position in BioLineRx during the 2nd quarter valued at about $462,000. PVG Asset Management Corp bought a new position in shares of BioLineRx during the second quarter valued at approximately $70,000. Finally, Atria Investments Inc increased its holdings in BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 29,193 shares during the period. 1.56% of the stock is currently owned by institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.